Fosbretabulin for the treatment of anaplastic thyroid cancer

被引：1
|
作者：
Granata, Roberta [1 ]
Locati, Laura D. [1 ]
Licitra, Lisa [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Milan, Italy
来源：
FUTURE ONCOLOGY | 2014年 / 10卷 / 13期
关键词：
anaplastic thyroid cancer; fosbretabulin; tubulin-binding agent; COMBRETASTATIN A-4 PHOSPHATE; A4; PHOSPHATE; PHASE-II; TRIAL; AGENT; PATHOGENESIS; MANAGEMENT; CARCINOMA; SCHEDULE;
D O I：
10.2217/FON.14.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
引用
收藏
页码：2015 / 2021
页数：7
相关论文
共 50 条
  • [21] Disparities in Presentation, Treatment, and Survival in Anaplastic Thyroid Cancer
    Ginzberg, Sara
    Passman, Jesse E.
    Ballester, Jacqueline M. Soegaard
    Finn, Caitlin B.
    Karakousis, Giorgos C.
    Kelz, Rachel R.
    Wachtel, Heather
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S116 - S116
  • [22] Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer
    Johnson, Jennifer M.
    Lai, Stephen Y.
    Cotzia, Paolo
    Cognetti, David
    Luginbuhl, Adam
    Pribitkin, Edmund A.
    Zhan, Tingting
    Mollaee, Mehri
    Domingo-Vidal, Marina
    Chen, Yunyun
    Campling, Barbara
    Bar-Ad, Voichita
    Birbe, Ruth
    Tuluc, Madalina
    Outschoorn, Ubaldo Martinez
    Curry, Joseph
    SEMINARS IN ONCOLOGY, 2015, 42 (06) : 915 - 922
  • [23] Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
    Nagaiah, Govardhanan
    Hossain, Akm
    Mooney, Colin J.
    Parmentier, James
    Remick, Scot C.
    JOURNAL OF ONCOLOGY, 2011, 2011
  • [24] Anaplastic thyroid cancer
    Ranganath, Rohit
    Shah, Manish A.
    Shah, Ashok R.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (05) : 387 - 391
  • [25] Dabrafenib and trametinib treatment for patients with anaplastic thyroid cancer
    Ito, Tokiko
    Amitani, Masatsugu
    Shimizu, Tadafumi
    Ono, Mayu
    Ohba, Takaaki
    Ohno, Koichi
    Kanai, Toshiharu
    Maeno, Kazuma
    Ito, Ken-Ichi
    ANNALS OF ONCOLOGY, 2021, 32 : S305 - S305
  • [26] Anaplastic thyroid cancer
    O'Neill, James Paul
    Shaha, Ashok R.
    ORAL ONCOLOGY, 2013, 49 (07) : 702 - 706
  • [27] Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer
    Sosa, Julie A.
    Balkissoon, Jai
    Lu, Shiao-ping
    Langecker, Peter
    Elisei, Rossella
    Jarzab, Barbara
    Bal, C. S.
    Marur, Shanthi
    Gramza, Ann
    Ondrey, Frank
    SURGERY, 2012, 152 (06) : 1078 - 1086
  • [28] Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy
    Jingjing Wang
    Jie Tan
    Bian Wu
    Ruolin Wu
    Yanmei Han
    Chenyang Wang
    Zairong Gao
    Dawei Jiang
    Xiaotian Xia
    Journal of Nanobiotechnology, 21
  • [29] Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy
    Wang, Jingjing
    Tan, Jie
    Wu, Bian
    Wu, Ruolin
    Han, Yanmei
    Wang, Chenyang
    Gao, Zairong
    Jiang, Dawei
    Xia, Xiaotian
    JOURNAL OF NANOBIOTECHNOLOGY, 2023, 21 (01)
  • [30] Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
    Anna Guerra
    Vincenzo Di Crescenzo
    Alfredo Garzi
    Mariapia Cinelli
    Chiara Carlomagno
    Massimo Tonacchera
    Pio Zeppa
    Mario Vitale
    BMC Surgery, 13
12345